Oncolytics Biotech (NASDAQ:ONCY) Downgraded by Leede Financial to “Moderate Buy”

Leede Financial cut shares of Oncolytics Biotech (NASDAQ:ONCY) from a strong-buy rating to a moderate buy rating in a research report released on Wednesday,Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Oncolytics Biotech in a research report on Thursday.

Oncolytics Biotech Price Performance

Oncolytics Biotech stock traded down $0.03 during mid-day trading on Wednesday, hitting $0.98. 245,358 shares of the company were exchanged, compared to its average volume of 328,224. The business’s 50 day simple moving average is $1.09 and its two-hundred day simple moving average is $1.06. The company has a market capitalization of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 12-month low of $0.84 and a 12-month high of $1.75.

Institutional Investors Weigh In On Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech at the end of the most recent quarter. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.